INVESTORS

Investor Relations

Recent News
Feb 6, 2020

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

Jan 22, 2020

- Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement -...

Dec 7, 2019

- New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting - - Analyst &...

View all news releases

Events and Webcasts
Sunday, December 8, 2019
7:00am - 8:00am EST

Hyatt Regency Orlando, Bayhill 33 Meeting Room
Dial-in Information:
Toll-Free: 1 (844) 467-7642
Toll: 1 (417) 385-2994
Conference ID: 3577956

View all events and webcasts

Investor Enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts